Quick Answer
Immuneering Corp reported Earnings Per Share Diluted of $1.27 (loss) per share for the year ending 2025.
- Immuneering Corp showed an increase of +37.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.73 (loss) per share | Q3 2020: $0.89 (loss) per share | Q1 2021: $1.26 (loss) per share | Q2 2021: $1.61 (loss) per share | Q3 2021: $0.47 (loss) per share | Q1 2022: $0.49 (loss) per share | Q2 2022: $0.44 (loss) per share | Q3 2022: $0.49 (loss) per share | Q1 2023: $0.51 (loss) per share | Q2 2023: $0.43 (loss) per share | Q3 2023: $0.43 (loss) per share | Q1 2024: $0.49 (loss) per share | Q2 2024: $0.47 (loss) per share | Q3 2024: $0.49 (loss) per share | Q1 2025: $0.42 (loss) per share | Q2 2025: $0.40 (loss) per share | Q3 2025: $0.38 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Immuneering Corp's Earnings Per Share Diluted has grown by 63.1%.
- Historical annual values: Fiscal year 2025: $1.27 (loss) per share | Fiscal year 2024: $2.04 (loss) per share | Fiscal year 2023: $1.88 (loss) per share | Fiscal year 2022: $1.91 (loss) per share | Fiscal year 2021: $2.46 (loss) per share | Fiscal year 2020: $3.44 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: